{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:04:12Z","timestamp":1775754252984,"version":"3.50.1"},"reference-count":38,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>ABBV-368 is a humanized monoclonal antibody that targets the costimulatory receptor OX40. Here, we investigate a treatment strategy with ABBV-368 combined with the investigational toll-like receptor 9 agonist tilsotolimod, the programmed cell death 1 inhibitor budigalimab, and nab-paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC). To our knowledge, this is the first clinical study in this setting to investigate chemotherapy combined with three immunotherapy agents, aiming to overcome failure of prior immune checkpoint inhibition and chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This phase 1b, multicenter, open-label study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04196283\">NCT04196283<\/jats:ext-link>\n                      ) enrolled adult patients with R\/M HNSCC into one of three treatment arms: ABBV-368 with tilsotolimod, ABBV-368 with tilsotolimod and nab-paclitaxel, or ABBV-368 with tilsotolimod, nab-paclitaxel, and budigalimab. Patients were treated in 28-day cycles. ABBV-368, nab-paclitaxel, and budigalimab were administered intravenously and tilsotolimod via intratumoral injection. Study objectives included safety, tolerability, pharmacokinetics, and preliminary antitumor activity. In addition, biomarker analyses were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 30 patients were enrolled; 16 received ABBV-368 plus tilsotolimod, 7 ABBV-368 plus tilsotolimod and nab-paclitaxel, and 7 ABBV-368 plus tilsotolimod, nab-paclitaxel, and budigalimab. In total, 80% of patients experienced any-grade adverse events related to ABBV-368. ABBV-368 and tilsotolimod induced peripheral interferon-gamma pathway upregulation, Th1 cytokine production, and T-cell activation that was not negatively impacted by nab-paclitaxel. There were no responses in the ABBV-368 plus tilsotolimod arm; one partial response was demonstrated in both the ABBV-368 plus tilsotolimod and nab-paclitaxel, and ABBV-368 plus tilsotolimod, nab-paclitaxel, and budigalimab arms, corresponding to an overall response rate of 14.3%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The quadruple combination of ABBV-368, tilsotolimod, nab-paclitaxel, and budigalimab was well tolerated and demonstrated pharmacodynamic activity. Several patients had disease stabilization, but clinical responses were limited. Initial priming and T-cell immune activation were inadequate to overcome prior therapy resistance mechanisms including a hypothesized unfavorable tumor microenvironment. Future work investigating strategies to target this inhibitory tumor microenvironment with optimally scheduled immunotherapy combinations in selected patients and indications is urgently needed to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04196283\">NCT04196283<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014086","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:15:26Z","timestamp":1775751326000},"page":"e014086","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent\/metastatic head and neck squamous cell carcinoma"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04196283","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04196283","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04196283","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05005403","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-812X","authenticated-orcid":false,"given":"Amaury","family":"Daste","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, CHU Bordeaux H\u00f4pital Saint-Andre, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Thoracic, Head, and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amani","family":"Makkouk","sequence":"additional","affiliation":[{"name":"AbbVie Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maulik","family":"Patel","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-6577","authenticated-orcid":false,"given":"Ruth","family":"Perets","sequence":"additional","affiliation":[{"name":"Rambam Medical Center and Technion \u2013 Israel Institute of Technology, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron","family":"Popovtzer","sequence":"additional","affiliation":[{"name":"Hadassah University Medical Center Sharett Institute of Oncology, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology and Comprehensive Cancer Center, Charit\u00e9 University Hospital Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlen","family":"Haderlein","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-8130","authenticated-orcid":false,"given":"Marc","family":"Oliva","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d\u2019Oncologia, L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1968-0459","authenticated-orcid":false,"given":"Ammar","family":"Sukari","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d\u2019Oncologia, L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaehyung","family":"Hong","sequence":"additional","affiliation":[{"name":"AbbVie Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Blaney","sequence":"additional","affiliation":[{"name":"AbbVie Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Ramathal","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McDevitt","sequence":"additional","affiliation":[{"name":"AbbVie Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari J","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology\/Oncology, The University of Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026040909151588000_14.4.e014086.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0227-z"},{"key":"2026040909151588000_14.4.e014086.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"2026040909151588000_14.4.e014086.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02508"},{"key":"2026040909151588000_14.4.e014086.4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.28526","article-title":"Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC","volume":"7","author":"Sun","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026040909151588000_14.4.e014086.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011"},{"key":"2026040909151588000_14.4.e014086.6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026040909151588000_14.4.e014086.7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12967-023-04504-w","article-title":"Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy","volume":"21","author":"Sun","year":"2023","journal-title":"J Transl Med"},{"key":"2026040909151588000_14.4.e014086.8","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy288.022","article-title":"Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors","volume":"29","author":"Spira","year":"2018","journal-title":"Ann Oncol"},{"key":"2026040909151588000_14.4.e014086.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.03.036"},{"key":"2026040909151588000_14.4.e014086.10","doi-asserted-by":"crossref","unstructured":"Park JC , Basak NP , Useche M , et al . Impact of pi3k pathway alterations on response to immune checkpoint inhibitors in hpv-negative head and neck squamous cell carcinoma. bioRxiv [Preprint] 2024. doi:10.1101\/2024.07.02.601738","DOI":"10.1101\/2024.07.02.601738"},{"key":"2026040909151588000_14.4.e014086.11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14712598.2023.2249396","article-title":"Challenges and opportunities in the development of combination immunotherapy with OX40 agonists","volume":"23","author":"Redmond","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2026040909151588000_14.4.e014086.12","first-page":"5079","article-title":"Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I\/II Trial (ILLUMINATE-101)","volume":"28","author":"Babiker","year":"2022","journal-title":"Cancer Res"},{"key":"2026040909151588000_14.4.e014086.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34676-w"},{"key":"2026040909151588000_14.4.e014086.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415434"},{"key":"2026040909151588000_14.4.e014086.15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1546"},{"key":"2026040909151588000_14.4.e014086.16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1158\/2767-9764.CRC-22-0050","article-title":"Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration","volume":"2","author":"Morinaga","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2026040909151588000_14.4.e014086.17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008378","article-title":"Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease","volume":"12","author":"Luke","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026040909151588000_14.4.e014086.18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejca.2021.08.004","article-title":"Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition","volume":"157","author":"Yuan","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026040909151588000_14.4.e014086.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1378"},{"key":"2026040909151588000_14.4.e014086.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102172"},{"key":"2026040909151588000_14.4.e014086.21","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2024.42.16_suppl.2521","article-title":"Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors","volume":"42","author":"Tolcher","year":"2024","journal-title":"JCO"},{"key":"2026040909151588000_14.4.e014086.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.75"},{"key":"2026040909151588000_14.4.e014086.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011524","article-title":"INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering","volume":"13","author":"Holay","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026040909151588000_14.4.e014086.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01265-5"},{"key":"2026040909151588000_14.4.e014086.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-024-10184-9"},{"key":"2026040909151588000_14.4.e014086.26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","article-title":"Regulatory T cells in tumor immunity","volume":"127","author":"Nishikawa","year":"2010","journal-title":"Intl Journal of Cancer"},{"key":"2026040909151588000_14.4.e014086.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7"},{"key":"2026040909151588000_14.4.e014086.28","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1158\/2159-8290.CD-24-1390","article-title":"Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade","volume":"15","author":"Jiang","year":"2025","journal-title":"Cancer Discov"},{"key":"2026040909151588000_14.4.e014086.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900696"},{"key":"2026040909151588000_14.4.e014086.30","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11112910","article-title":"CCR8 as a Therapeutic Novel Target: Omics-Integrated Comprehensive Analysis for Systematically Prioritizing Indications","volume":"11","author":"Kim","year":"2023","journal-title":"Biomedicines"},{"key":"2026040909151588000_14.4.e014086.31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-med-043024-123559","article-title":"Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development","volume":"77","author":"Navarrete","year":"2026","journal-title":"Annu Rev Med"},{"key":"2026040909151588000_14.4.e014086.32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.it.2025.01.001","article-title":"CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells","volume":"46","author":"Wen","year":"2025","journal-title":"Trends Immunol"},{"key":"2026040909151588000_14.4.e014086.33","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14069"},{"key":"2026040909151588000_14.4.e014086.34","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e3","article-title":"Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy","volume":"20","author":"Jeong","year":"2020","journal-title":"Immune Netw"},{"key":"2026040909151588000_14.4.e014086.35","first-page":"6165","article-title":"Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40","volume":"23","author":"Messenheimer","year":"2017","journal-title":"Cancer Res"},{"key":"2026040909151588000_14.4.e014086.36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0292"},{"key":"2026040909151588000_14.4.e014086.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.12.013"},{"key":"2026040909151588000_14.4.e014086.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0224-x"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:15:29Z","timestamp":1775751329000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jitc-2025-014086"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014086","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}